G protein-coupled receptor transmembrane binding pockets and their applications in GPCR research and drug discovery: A survey

Current Topics in Medicinal Chemistry

Volumn 11, Issue 15, 2011, Pages 1902-1924

  Kratochwil, Nicole A ^a   Gatti Mcarthur, Silvia ^a   Hoener, Marius C ^a   Lindemann, Lothar ^a   Christ, Andreas D ^a   Green, Luke G ^a   Guba, Wolfgang ^a   Martin, Rainer E ^a   Malherbe, Pari ^a   Porter, Richard H P ^a   Slack, Jay P ^b   Winnig, Marcel ^c   Dehmlow, Henrietta ^a   Grether, Uwe ^a   Hertel, Cornelia ^a   Narquizian, Robert ^a   Panousis, Constantinos G ^a   Kolczewski, Sabine ^a   Steward, Lucinda ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Givaudan Roure Corporation   (United States)

^c Axxam   (Italy)

Author keywords

5 hydroxytryptamine receptors; Chemogenomics; GPCR; Ligand binding pocket; Melanopsins; Metabotropic gluta mate receptors; Nicotinic acid family receptors; Pharmacophore modeling; Somatostatin receptors; Sweet taste receptor; Trace amine associated receptors

Indexed keywords

AMINO ACID; AMPHETAMINE; ASPARTAME; ASTEMIZOLE; CYCLAMATE SODIUM; FLUSPIRILENE; G PROTEIN COUPLED RECEPTOR; HYDROXYAMPHETAMINE; LOPERAMIDE; MELANOPSIN; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; METHAMPHETAMINE; NICOTINIC ACID; OCTOPAMINE; PHENETHYLAMINE; SEROTONIN AGONIST; SOMATOSTATIN RECEPTOR 5; TRYPTAMINE; TYRAMINE;

ARTICLE; AUTOMATION; DRUG INDUSTRY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; IC 50; IN VITRO STUDY; LIGAND BINDING; PHARMACOPHORE; TASTE BUD;

AMINO ACID SEQUENCE; BINDING SITES; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED;

EID: 79960566597     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796391267     Document Type: Article

References (160)

1. Defea, K. Beta-arrestins and heterotrimeric G-proteins: collabora tors and competitors in signal transduction. Br. J. Pharmacol., 2008, 153, 298-309.
2. Rosenbaum, D.M.; Rasmussen, S.G.F.; Kobilka, B.K. The structure and function of G-protein-coupled receptors. Nature, 2009, 459, 356-363.
3. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, H.; Fox, B.A.; Le Trong, I.; Teller, D.C.; Okada, T.; Stenkamp, R.E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289, 739-745.
4. Unger, V.M.; Hargrave, P.A.; Baldwin, J.M.; Schertler, G.F.X. Arrangement of rhodopsin transmembrane alpha-helices. Nature, 1997, 389, 203-206.
5. Warne, T.; Serrano-Vega, M.J.; Baker, J.G.; Moukhametzianov, R.; Edwards, P.C.; Henderson, R.; Leslie, A. G.; Tate, C.G.; Schertler, G.F. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature, 2008, 454, 486-491.
6. Cherezov, V.; Rosenbaum, D.M.; Hanson, M.A.; Rasmussen, S.G.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Kuhn, P.; Weis, W.I.; Ko-bilka, B.K.; Stevens, R.C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science, 2007, 318, 1258-1265.
7. Rasmussen, S.G.; Choi, H.J.; Rosenbaum, D.M.; Kobilka, T.S.; Thian, F.S.; Edwards, P.C.; Burghammer, M.; Ratnala, V.R.; San-ishvili, R.; Fischetti, R.F.; Schertler, G.F.; Weis, W.I.; Kobilka, B.K. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature, 2007, 450, 383-387.
8. Rosenbaum, D.M.; Cherezov, V.; Hanson, M.A.; Rasmussen, S.G.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Yao, X.J.; Weis, W.I.; Stevens, R.C.; Kobilka, B.K. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science, 2007, 318, 1266-1273.
9. Jaakola, V.P.; Griffith, M.T.; Hanson, M.A.; Cherezov, V.; Chien, E.Y.; Lane, J.R.; Ijzerman, A.P.; Stevens, R.C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 2008, 322, 1211-1217.
10. Park, J.H.; Scheerer, P.; Hofmann, K.P.; Choe, H.W.; Ernst, O.P. Crystal structure of the ligand-free G-protein-coupled receptor op-sin. Nature, 2008, 454, 183-187.
11. Scheerer, P.; Park, J.H.; Hildebrand, P.W.; Kim, Y.J.; Krauss, N.; Choe, H.W.; Hofmann, K.P.; Ernst, O.P. Crystal structure of opsin in its G-protein-interacting conformation. Nature, 2008, 455, 497-502.
12. Hanson, M.A.; Stevens, R.C. Discovery of new GPCR biology: One receptor structure at a time. Structure, 2009, 17, 8-14.
13. Millar, R.P. Newton, C.L. The Year in G protein-coupled receptor research. Mol. Endocrinol., 2010, 24, 261.
14. Ballesteros, J.A.; Shi, L.; Javitch, J.A. Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol., 2001, 60, 1-19.
15. Oliveira, L.; Paiva, A.C.M.; Vriend, G. Correlated mutation analysis on very large sequence families. ChemBioChem, 2002, 3, 1010-1017.
16. Bondensgaard, K.; Ankersen, M.; Thøgersen, H.; Hansen, B.S.; Wulff, B.S. Recognition of privileged structures by G-protein coupled receptors. J. Med. Chem., 2004, 47, 888-899.
17. Mirzadegan, T.; Benko, G.; Filipek, S.; Palczewski, K. Sequence analysis of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry, 2003, 42, 2759-2767.
18. Kristiansen, K.; Dahl, S.G.; Edvardsen, Ø. A database of mutants and effects of site-directed mutagenesis experiments on G-protein coupled receptors. Proteins: Struct., Funct., Bioinf., 1996, 26, 81-94.
19. Shi, L.; Javitch, J.A. The binding site of aminergic G protein-coupled receptors: The transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol., 2002, 42, 437-467.
20. Visiers, I.; Ballesteros, J.A.; Weinstein, H. Three-dimensional representation of G protein-coupled receptor structures and mechanisms. Methods Enzymol., 2001, 343, 329-371.
21. Gether, U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocrine Rev., 2000, 21, 90-113.
22. Lu, Z.-L.; Saldanha, J.W.; Hulme, E.C. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol. Sci., 2002, 23, 140-146.
23. Huang, E.S. Construction of a sequence motif characteristic of aminergic G protein-coupled receptors. Prot. Sci., 2003, 12, 1360-1367.
24. Lapinsh, M.; Gutcaits, A.; Prusis, P.; Post, C.; Lundstedt, T. Classification of G-protein coupled receptors by alignment-independent extraction of principal chemical properties of primary amino acid sequences. Prot. Sci., 2002, 11, 795-805.
25. Lapinsh, M.; Prusis, P.; Lundstedt, T.; Wikberg, J.E.S. Proteo-chemometrics modeling of the interaction of amine G-protein coupled receptors with a diverse set of ligands. Mol. Pharmacol., 2002, 61, 1465-1475
26. Jacoby, E. A novel chemogenomics knowledge-based ligand design strategy-Application to G protein-coupled receptors. Quant. Struct.-Act. Relat., 2001, 20, 115-123.
27. Madabushi, S.; Gross, A. K.; Philippi, A.; Meng, E. C.; Wensel, T. G.; Lichtarge, O. Evolutionary trace of G protein-coupled receptors reveals clusters of residues that determine global and class-specific functions. J. Biol. Chem., 2004, 279, 8126-8132.
28. Kratochwil, N.A.; Malherbe, P.; Lindemann, L.; Ebeling, M.; Hoe-ner, M.C.; Muehlemann, A.; Porter, R.H. P.; Stahl, M.; Gerber, P.R. An automated system for the analysis of G protein-coupled receptor transmembrane binding pockets: alignment, receptor-based pharmacophores, and their application. J. Chem. Inf. Model, 2005, 45, 1324-1336.
29. Gasteiger, E.; Gattiker, A.; Hoogland, C.; Ivanyi, I.; Appel, R.D.; Bairoch, A. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res., 2003, 31, 3784-3788.
30. Ballesteros, J. A.; Weinstein, H. Integrated methods and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci., 1995, 25, 366-428. In analogy to the Ballesteros-Weinstein helix numbering scheme for TM helices, ECL2 is labeled "45" to indicate its location between helices 4 and 5. The highly conserved cysteine, thought to be disulfide-bonded, was given the index 45.50, and the residues within ECL2 were then indexed relative to this ".50" position.
31. Kristiansen, K.; Dahl, S.G.; Edvardsen, Ø. A database of mutants and effects of site-directed mutagenesis experiments on G-protein coupled receptors. Proteins: Struct., Funct., Bioinf., 1996, 26, 81-94.
32. Gerber, P.R. Topological Pharmacophore Description of Chemical Structures using MAB-Force-Field-Derived Data and Corresponding Similarity Measures. In: Fundamentals of Molecular Similarity; Carbó-Dorca, R.; Gironés, X.; Mezey, P.G.; Eds., Kluwer Academic/Plenum Publishers: New York, 2001; pp. 67-81.
33. Lovell, S. C.; Word, J. M.; Richardson, J. S.; Richardson, D. C. The Penultimate Rotamer Library. Proteins: Struct., Funct., Bioin-formatics, 2000, 40, 389-408.
34. Peirson, S.; Foster, R.G. Melanopsin: Another way of signaling light. Neuron, 2006, 49, 1-9.
35. Hankins, M.W.; Peirson, S.N.; Foster, R.G. Melanopsin: an exciting photopigment. Trends Neurosci., 2007, 31, 27-36.
36. Paul, K.N.; Saafir, T.B.; Tosini, G. The role of retinal photorecep-tors in the regulation of circadian rhythms. Rev. Endocr. Metab. Disord., 2009, 10, 271-278.
37. Yeom, M.; Pendergast, J.S.; Ohmiya, Y.; Yamazaki, S. Circadian-independent cell mitosis in immortalized fibroblasts. Proc. Natl. Acad. Sci. USA, 2010, 107, 9665-9670.
38. Bellingham, J.; Foster, R.G. Opsins and mammalian photoentrain-ment. Cell Tissue Res., 2002, 309, 57-71.
39. Borowsky, B.; Adham, N.; Jones, K.A.; Raddatz, R.; Artymyshyn, R.; Ogozalek, K.L.; Durkin, M.M.; Lakhlani, P.P.; Bonini, J.A.; Pathirana, S.; Boyle, N.; Pu, X.; Kouranova, E.; Lichtblau, H.; Ochoa, F. Y.; Branchek, T.A.; Gerald, C. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc. Natl. Acad. Sci. USA, 2001, 98, 8966-8971.
40. Sotnikova, T.D.; Caron, M.G.; Gainetdinov, R.R. Trace amine-associated receptors as emerging therapeutic targets. Mol. Pharmacol., 2009, 76, 229-235.
41. Lindemann, L.; Ebeling, M.; Kratochwil, N.A.; Bunzow, J.R.; Grandy, D.K.; Hoener, M.C. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics, 2005, 85, 372-385.
42. Lindemann, L.; Hoener, M.C. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol. Sci., 2005, 26, 274-281.
43. Maguire, J.J.; Parker, W.A. E.; Foord, S.M.; Bonner, T.I.; Neubig, R.R.; Davenport, A.P. International union of pharmacology. LXXII. Recommendations for trace amine receptor nomenclature. Pharmacol. Rev., 2009, 61,1-8.
44. Lindemann, L.; Meyer, C.A.; Jeanneau, K.; Bradaia, A.; Ozmen, L.; Bluethmann, H.; Bettler, B.; Wettstein, J.G.; Borroni, E.; Mo-reau, J.L.; Hoener, M.C. Trace amine-associated receptor 1 modulates dopaminergic activity. J. Pharmacol. Exp. Ther., 2008, 324, 948-956.
45. Bradaia, A.; Trube, G.; Stalder, H.; Norcross, R.D.; Ozmen, L.; Wettstein, J.G.; Pinard, A.; Buchy, D.; Gassmann, M.; Hoener, M.C.; Bettler, B. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc. Natl. Acad. Sci. USA, 2009, 106, 20081-20086.
46. Liberles, S.D.; Buck, L.B. A second class of chemosensory receptors in the olfactory epithelium. Nature, 2006, 442, 645-650.
47. Vallender, E.J.; Xie, Z.; Westmoreland, S.V.; Miller, G.M. Functional evolution of the trace amine associated receptors in mammals and the loss of TAAR1 in dogs. BMC Evolutionary Biol., 2010, 10, 51.
48. Wainscott, D.B.; Little, S.P.; Yin, T.; Tu, Y.; Rocco, V.P.; He, J.X.; Nelson, D.L. Pharmacologic characterization of the cloned human trace amine-associated receptor 1 (TAAR1) and evidence for species differences with the rat TAAR1. J. Pharmacol. Exp. Ther., 2007, 320, 475-485.
49. Reese, E.A; Bunzow, J.R.; Arttamangkul, S.; Sonders, M.S.; Grandy, D.K. Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J. Pharmacol. Exp. Ther., 2007, 321, 178-186.
50. Tan, E.S.; Naylor, J.C.; Groban, E.S.; Bunzow, J.R; Jacobson, M.P.; Grandy, D.K.; Scanlan, T.S. The molecular basis of species-specific ligand activation of trace amine-associated receptor 1 (TAAR1). ACS Chem. Biol., 2009, 4, 209-220.
51. Wolkenberg, S.E.; Thut, C.J. Recent progress in the discovery of selective, non-peptide ligands of somatostatin receptors. Curr. Opin. Drug Discov. Devel., 2008, 11, 446-457.
52. Dalm, V.A.S.H.; Hofland, L.J.; Lamberts, S.W.J. Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field. Mol. Cell Endocrinol., 2008, 286, 262-277
53. van der Hoek, J.; Lamberts, S.W.J.; Hofland, L.J. The somatostatin receptor subtype 5 in neuroendocrine tumours. Expert Opin. Inves-tig. Drugs, 2010, 19, 385-399.
54. Sprecher, U.; Mohr, P.; Martin, R.E.; Maerki, H.P.; Sanchez, R.A.; Binggeli, A.; Kuennecke, B.; Christ, A.D. Novel, non-peptidic so-matostatin receptor subtype 5 antagonists improve glucose tolerance in rodents. Regulatory Peptides, 2010, 159, 19-27.
55. LOPAC. Library of Pharmacologically Active Compounds.http://www.sigmaaldrich.com(Accessed June 16, 2010).
56. BioPrint is a registered trademark of Cerep SA. http://www.cerep.com (Accessed June 16, 2010).
57. Surgand, J.-S.; Rodrigo, J.; Kellenberger, E.; Rognan, D.A. Che-mogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins: Struct., Funct., Bioinf., 2006, 62, 509-538.
58. Fredriksson, R.; Lagerstrom, M.C.; Lundin, L.G.; Schioth, H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol., 2003, 63, 1256-1272.
59. Martin, R.E.; Green, L.G.; Guba, W.; Kratochwil, N.; Christ, A. Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: A chemogenomics approach. J. Med. Chem., 2007, 50, 6291-6294.
60. Duran-Prado, M.; Malagon, M.M.; Gracia-Navarro, F.; Castano, J.P. Dimerization of G protein-coupled receptors: New avenues for somatostatin receptor signaling, control and functioning. Mol. Cell. Endocrinol., 2008, 286, 63-68.
61. Jaquet, P.; Gunz, G.; Saveanu, A.; Barlier, A.; Dufour, H.; Taylor, J.; Dong, J.; Kim, S.; Moreau, J.P.; Culler, M.D. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J. Endocrinol. Invest., 2005, 28,21-27.
62. Chanson, P. Emerging drugs for acromegaly. Expert Opin. Emerg. Drugs, 2008, 13, 273-293.
63. Pin, J.-P.; Kniazeff, J.; Liu, J.; Binet, V.; Goudet, C.; Rondard, P.; Prezeau, L. Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J., 2005, 272, 2947-2955.
64. Kunishima, N.; Shimada, Y.; Tsuji, Y.; Sato, T.; Yamamoto, M.; Kumasaka, T.; Nakanishi, S.; Jingami, H.; Morikawa, K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature, 2000, 407, 971-977.
65. Tsuchiya, D.; Kunishima, N.; Kamiya, N.; Jingami, H.; Morikawa, K. Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both gluta-mate and Gd3+. Proc. Natl. Acad. Sci. USA, 2002, 99, 2660-2665.
66. Muto, T.; Tsuchiya, D.; Morikawa, A.; Jingami, H. Structures of the extracellular regions of the group 2/3 metabotropic glutamate receptors. Proc. Natl. Acad. Sci. USA, 2007, 104, 3759-3764.
67. Ferraguti, F.; Crepaldi, L.; Nicoletti, F. Metabotropic glutamate 1 receptor: current concepts and perspectives. Pharmacol. Rev., 2008, 60, 536-581.
68. Gravius, A.; Pietraszek, M.; Dekundy, A.; Danysz, W. Me-tabotropic glutamate receptors as therapeutic targets for cognitive disorders. Curr. Top. Med. Chem., 2010, 10, 187-206.
69. Byrnes, K.R.; Loane, D.J.; Faden, A.I. Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders. Neurotherapeutics, 2009, 6, 94-107.
70. Conn, P.J.; Christopoulos, A.; Lindsley, C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov., 2009, 8, 41-54.
71. Nordquist, R.E.; Steckler, T.; Wettstein, J.G.; Mackie, C.; Spooren, W. Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety. Psychophar-macology, 2008, 199, 389-402.
72. Niswender, C.M.; Conn, P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol., 2010, 50, 295-322.
73. Conn, P.J.; Lindsley, C.W.; Jones, C.K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci., 2009, 30, 25-31.
74. Pagano, A.; Ruegg, D.; Litschig, S.; Stoehr, N.; Stierlin, C.; Hein-rich, M.; Floersheim, P.; Prezeau, L.; Carroll, F.; Pin, J.-P.; Cambria, A.; Vranesic, I.; Flor, P.J.; Gasparini, F.; Kuhn, R. The non-competitive antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem., 2000, 275, 33750-33758.
75. Malherbe, P.; Kratochwil, N.; Knoflach, F.; Zenner, M.-T.; Kew, J.N.C.; Kratzeisen, C.; Maerki, H.P.; Adam, G.; Mutel, V. Muta-tional analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J. Biol. Chem., 2003, 278, 8340-8347.
76. Malherbe, P.; Kratochwil, N.; Zenner, M.-T.; Piussi, J.; Diener, C.; Kratzeisen, C.; Fischer, C.; Porter, R.H.P. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glu-tamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)pyridine. Mol. Pharmacol., 2003, 64, 823-832.
77. Malherbe, P.; Kratochwil, N.; Muhlemann, A.; Zenner, M.-T.; Fischer, C.; Stahl, M.; Gerber, P.R.; Jaeschke, G.; Porter, R.H.P. Comparison of the binding pockets of two chemically unrelated al-losteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. J. Neuro-chem., 2006, 98, 601-615.
78. Porter, R.H.P.; Jaeschke, G.; Spooren, W.; Ballard, T.M.; Buettel-mann, B.; Kolczewski, S.; Peters, J.-U;. Prinssen, E.; Wichmann, J.; Vieira, E.; Muehlemann, A.; Gatti, S.; Mutel, V.; Malherbe, P. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther., 2005, 315, 711-721.
79. Muehlemann, A.; Ward, N.A.; Kratochwil, N.; Diener, C.; Fischer, C.; Stucki, A.; Jaeschke, G.; Malherbe, P.; Porter, R.H.P. Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors. Eur. J. Pharmacol., 2006, 529, 95-104.
80. de Graaf, C.; Rognan, D. Customizing G protein-coupled receptor models for structure-based virtual screening. Curr. Pharm. Des., 2009, 15, 4026-4048.
81. Michino, M.; Abola, E.; GPCR Dock 2008 participants, Brooks, C. L.; Dixon, J. S.; Moult, J.; Stevens, R. C. Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat. Rev. Drug Discov., 2008, 8, 455-463.
82. McGovern, S.L.; Shoichet, B.K. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J. Med. Chem., 2003, 46, 2895-2907.
83. May, T.; Leach, K.; Sexton, P.M.; Christopoulos, A. Allosteric modulation of G-protein-coupled receptors, Annu. Rev. Pharmacol. Toxicol., 2007, 47, 1-51.
84. Raddatz, R.; Schaffhauser, H.; Marino, M.J. Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: A critical assessment. Biochem. Pharmacol., 2007, 74, 383-391.
85. De Amici, M.; Dallanoce, C.; Holzgrabe, U.; Trankle, C.; Mohr, K. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med. Res. Rev., 2010, 30, 463-549.
86. DuBois, G.E. In: Sweetness and Sweeteners. Biology, Chemistry, and Psychophysics; Weerasinghe, D.K.; DuBois, G.E.; Eds.; ACS Symposium Series; American Chemical Society: Washington, DC, 2008; Vol. 979, pp. 1-16.
87. Temussi, P.A. Sweet, bitter and umami receptors: a complex relationship. Trends Biochem. Sci., 2009, 34, 296-302.
88. Meyers, B.; Brewer, M.S. Sweet taste in man: a review. J. Food Sci., 2008, 73, R81-R90.
89. Jiang, P.; Cui, M.; Zhao, B.; Snyder, L.A.; Benard, L.M.; Osman, R.; Max, M.; Margolskee, R.F. Identification of the cyclamate interaction site within the transmembrane domain of the human sweet taste receptor subunit T1R3. J. Biol. Chem., 2005, 280, 34296-34305.
90. DuBois, G. E. Unraveling the biochemistry of sweet and umami tastes. Proc. Natl. Acad. Sci. USA, 2004, 101, 13972-13973.
91. Jiang, P.; Cui, M.; Zhao, B.; Liu, Z.; Snyder, L.A.; Benard, L.M.; Osman, R.; Margolskee, R.F.; Max, M. Lactisole interacts with the transmembrane domains of human T1R3 to inhibit sweet taste. J. Biol. Chem., 2005, 280, 15238-15246.
92. Winnig, M.; Bufe, B.; Kratochwil, N.A.; Slack, J.P.; Meyerhof, W. The binding site for neohesperidin dihydrochalcone at the human sweet taste receptor. BMC Struct. Biol., 2007, 7, 66.
93. Whitelaw, M.L.; Chung, H.J.; Daniel, J.R. Synthesis and sensory evaluation of ring-substituted dihydrochalcone sweeteners. 2. Analogues of 3'-Carboxyhesperetin dihydrocahlcone, a high potency dihydrochalcone sweetener. J. Agric. Food Chem., 1991, 39, 663-667.
94. Whitelaw, M.L.; Daniel, J.R. Synthesis and sensory evaluation of ring-substituted dihydrochalcone sweeteners. J. Agric. Food Chem., 1991, 39, 44-51.
95. Xu, H.; Staszewski, L.; Tang, H.; Adler, E.; Zoller, M.; Li, X. Different functional roles of T1R subunits in the heteromeric taste receptors. Proc. Natl. Acad. Sci. USA, 2004, 101, 14258-14263.
96. Rodriguez, G.J.; Yao, R.; Lichtarge, O.; Wensel, T.G. Evolution-guided discovery and recoding of allosteric pathway specificity determinants in psychoactive bioamine receptors. Proc. Natl. Acad. Sci. USA, 2010, 107, 7787-7792.
97. del Burgo, L.S.; Milligan, G. Heterodimerisation of G protein-coupled receptors: implications for drug design and ligand screening. Expert Opin. Drug Discov., 2010, 5, 461-474.
98. Franco, R.; Canela, E.I.; Casado, V.; Ferre, S. Platforms for the identification of GPCR targets, and of orthosteric and allosteric modulators. Expert Opin. Drug Discov., 2010, 5, 391-403.
99. Casado, V.; Cortes, A.; Mallol, J.; Perez-Capote, K.; Ferre, S.; Lluis, C.; Franco, R.; Canela, E.I. GPCR homomers and hetero-mers: A better choice as targets for drug development than GPCR monomers? Pharmacol. Ther., 2009, 124, 248-257.
100. Kenakin, T.P. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat. Rev. Drug Discov., 2009, 8, 617-626.
101. Ahmed, K.; Tunaru, S.; Offermanns, S. GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors. Trends Pharmacol. Sci., 2009, 30, 557-562
102. Gille, A.; Bodor, E.T.; Ahmed, K.; Offermanns, S. Nicotinic acid: Pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 79-106.
103. Tunaru, S.; Lättig, J.; Kero, J.; Krause, G.; Offermanns, S. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol. Pharmacol., 2005, 68, 1271-1280.
104. Wise, A.; Foord, S.M.; Fraser, N.J.; Barnes, A.A.; Elshourbagy, N.; Eilert, M.; Ignar, D.M.; Murdock, P.R.; Steplewski, K.; Green, A.; Brown, A.J.; Dowell, S.J.; Szekeres, P.G.; Hassall, D.G.; Marshall, F.H; Wilson, S.; Pike, N.B. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem., 2003, 278, 9869-9874.
105. Rajnikant; Dinesh; Kamni; Deshmukh, M.B. Synthesis and X-ray structure analysis of 2-acetylamino-benzoic acid. J. Chem. Crystal-logr., 2004, 34, 471-475.
106. Chakravarty, S.; &/x&&namegr type=editor&&name&&sname&Dugar&/sname&&x&, &/x&&fname&S.&/fname&&/name&&x&; &/x&&name&&sname&Tester&/sname&&x&, &/x&&fname&R.&/fname&&/name&&x&; &/x&&name&&sname&Conte&/sname&&x&, &/x&&fname&A&/fname&&/name&&/namegr&. Preparation of pyridopyrimidones. PCT Int. Appl., 2005065416, September 15, 2005.
107. Conte, A.; Dehmlow, H.; Grether, U.; Kratochwil, N.A.; Kuehne, H.; Narquizian, R.; Panousis, C.G.; Peters, J.U.; Ricklin, F. Roever, S. Preparation of pyrido[2,3-d]pyrimidin-4-one derivatives as HM74A agonists. PCT Int. Appl., 2007134986, November 29, 2007.
108. Campbell, M.; Hatley, Richard J.; Heer, J.P.; Mason, A.M.; Nicholson, N.H.; Pinto, I.L.; Rahman, S.S.; Smith, I.E.D. Preparation of anthranilic acid derivatives as selective agonists of the nicotinic acid receptor HM74A. PCT Int. Appl., 2005016870, February 24, 2005.
109. Conte, A.; Dehmlow, H.; Grether, U.; Kratochwil, N.A.; Kuehne, H.; Narquizian, R.; Panousis, C.G.; Peters, J.U.; Ricklin, F. Preparation of novel aza-pyrido pyrimidinone derivatives as G-protein coupled receptor (HM74A) agonists. U.S. Patent 20080234277, September 25, 2008.
110. Dehmlow, H.; Grether, U.; Kratochwil, N.A; Narquizian, R.; Panousis, C.G. Preparation of acylaminothiophenecarboxylates as HM74A agonists. U.S. Patent 20070161650, July 12, 2007.
111. Dehmlow, H.; Grether, U.; Kratochwil, N.A; Narquizian, R.; Panousis, C. G. Preparation of acylaminothiophenecarboxylates as HM74A agonists. U.S. Patent 20070072873, March 29, 2007.
112. Dehmlow, H.; Grether, U.; Kratochwil, N.A; Narquizian, R.; Panousis, C G.; Peters, J.U. Preparation of benzoylanthranilic acid derivatives as G protein-coupled receptor HM74A agonists. U.S. Patent 20060281810, December 14, 2006.
113. Peters, J.U.; Kühne, H.; Dehmlow, H.; Grether, U., Conte, A.; Hainzl, D.; Hertel, C.; Kratochwil, N.A.; Otteneder, M.; Narquiz-ian, R.; Panousis, C.G.; Ricklin, F.; Röver, S. Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: Optimisation of in vitro activity. Bioorg. Med. Chem. Lett., 2010, 20(18), 5426-5430.
114. Nichols, D.E.; Nichols, C.D. Serotonin receptors. Chem. Rev., 2008, 108, 1614-1641.
115. Thomas, D.R. 5-ht5A receptors as a therapeutic target. Pharmacol. Ther., 2006, 111, 707-714.
116. Peters, J.U.; Lübbers, T.; Alanine, A.; Kolczewski, S.; Blasco, F.; Steward, L. Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg. Med. Chem. Lett., 2008, 18, 256-261.
117. Steward, L.; Kratochwil, N.A.; Hamm, C.; Py, G.; Henriot, S.; Anastasi, N.; Wettstein, J.G.; Kolczewski, S.; Roche, O. Design of 5-ht5A receptor antagonists (2-aminoquinolines): impact of muta- tional analysis and receptor pharmacophore modelling on specificity and selectivity. Manuscript in preparation.
118. Kolczewski, S.; Riemer, C.; Roche, O.; Steward, L.; Wichmann, J.; Woltering, T. Preparation of 2-aminoquinolines as 5-HT5A receptor antagonists. PCT Int. Appl., 2009112395, September 17, 2009.
119. Kolczewski, S.; Riemer, C.; Roche, O.; Steward, L.; Wichmann, J.; Woltering, T. Preparation of 2-aminoquinoline derivatives as 5-HT5A receptor antagonists. PCT Int. Appl., 2009109491, September 11, 2009.
120. Kolczewski, S.; Riemer, C.; Roche, O.; Steward, L.; Wichmann, J.; Woltering, T. Preparation of 2-aminoquinoline derivatives as 5-HT5A receptor antagonists. PCT Int. Appl., 2009109493, September 11, 2009.
121. Kolczewski, S.; Riemer, C.; Roche, O.; Steward, L.; Wichmann, J.; Woltering, T. Preparation of 2-aminoquinoline derivatives as 5-HT5A receptor antagonists. PCT Int. Appl., 2009109502, September 11, 2009.
122. Kolczewski, S.; Riemer, C.; Roche, O.; Steward, L.; Wichmann, J.; Woltering, T. Preparation of 2-aminoquinoline derivatives as 5-HT5A receptor antagonists. PCT Int. Appl., 2009109477, September 11, 2009.
123. Kolczewski, S.; Riemer, C.; Steward, L.; Wichmann, J.; Woltering, T. Preparation of quinoline derivatives as 5HT5A receptor antagonists. PCT Int. Appl., 2009040290, April 02, 2009.
124. Kolczewski, S.; Riemer, C.; Steward, L.; Wichmann, J.; Woltering, T. Preparation of 2-aminoquinolines as 5-HT5A receptor antagonists. PCT Int. Appl., 2008068157, June 12, 2008.
125. Malherbe, P.; Bissantz, C.; Marcuz, A.; Kratzeisen, C.; Zenner, M.-T.; Wettstein, J. G.; Ratni, H.; Riemer, C.; Spooren, W. Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains. Mol. Pharmacol., 2008, 73, 1736-1750.
126. Malherbe, P.; Kratzeisen, C.; Marcuz, A.; Zenner, M.-T; Net-tekoven, M. H.; Ratni, H.; Wettstein, J. G.; Bissantz, C. Identification of a Critical Residue in the Transmembrane Domain 2 of Tachykinin Neurokinin 3 Receptor Affecting the Dissociation Kinetics and Antagonism Mode of Osanetant (SR 142801) and Piperidine-Based Structures. J. Med. Chem., 2009, 52, 7103-7112.
127. Malherbe, P.; Roche, O.; Marcuz, A.; Kratzeisen, C.; Wettstein, J. G.; Bissantz, C. Mapping the binding pocket of dual antagonist Almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Mol. Pharmacol., 2010, 78, 81-93.
128. Ratni, H.; Ballard, T. M.; Bissantz, C.; Hoffmann, T.; Jablonski, P.; Knoflach, F.; Knust, H.; Malherbe, P.; Nettekoven, M.; Patiny-Adam, A.; Riemer, C.; Schmitt, M.; Spooren, W. Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonists. Bioorg. Med. Chem. Lett., 2010, 20, 6735-6738.
129. Lundström, L.; Bissantz, C.; Beck, J.; Wettstein, J. G.; Woltering, T. J.; Wichmann, J.; Gatti, S. Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. Br. J. Pharmacol., 2011, April 6 [Epub ahead of print].
130. Gloriam, D.E.; Foord, S.M.; Blaney, F.E.; Garland, S.L. Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. J. Med. Chem., 2009, 52, 4429-4442.
131. Marquez, V. E.; Nacro, K.; Benzaria, S.; Lee, J.; Sharma, R. The transition from a pharmacophore-guided approach to a receptor-guided approach in the design of potent protein kinase C ligands. Pharmacol. Ther., 1999, 82, 251-261.
132. Kirchhoff, P.D.; Brown, R.; Kahn, S.; Waldman, M.; Venkatacha-lam, C.M. Application of structure-based focusing to the estrogen receptor. J. Comput. Chem., 2001, 22, 993-1003.
133. Ahlstrom, M.M.; Ridderstrom, M.; Luthman, K.; Zamora, I. Virtual screening and scaffold hopping based on GRID molecular interaction fields. J. Chem. Inf. Model, 2005, 45, 1313-1323.
134. Schuller, A.; Fechner, U.; Renner, S.; Franke, L.; Weber, L.; Schneider, G. A pseudo-ligand approach to virtual screening. Comb. Chem. High Throughput Screen., 2006, 9, 359-364.
135. Steindl, T. M.; Schuster, D.; Laggner, C.; Langer, T. Parallel screening: a novel concept in pharmacophore modeling and virtual screening. J. Chem. Inf. Model., 2006, 46, 2146-2157.
136. Chen, J.; Lai, L. Pocket v.2: further developments on receptor-based pharmacophore modeling. J. Chem. Inf. Model., 2006, 46, 2684-2691.
137. Baroni, M.; Cruciani, G.; Sciabola, S.; Perruccio, F.; Mason, J.S. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for ligands and proteins (FLAP): Theory and application. J. Chem. Inf. Model., 2007, 47, 279-294.
138. Guido, R.V.C.; Castilho, M.S.; Oliva, G.; Andricopulo, A.D. Structure-based pharmacophore strategies in drug design. In: Current Methods in Medicinal Chemistry and Biological Physics; Taft, C. A., Carlos; Silva, C.H.T.P., Eds.; Research Signpost, 2008, 2, pp. 93-112.
139. Klabunde, T.; Giegerich, C.; Evers, A. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. J. Med. Chem., 2009, 52, 2923-2932.
140. Gao, Q.; Yang, L.; Zhu, Y. Pharmacophore based drug design approach as a practical process in drug discovery. Curr. Comput. Aided Drug Des., 2010, 6, 37-49.
141. Mason, J.S.; Good, A.C.; Martin, E.J. 3-D pharmacophores in drug discovery. Curr. Pharm. Des., 2001, 7, 567-597.
142. Kim, K.-H.; Kim, N.D.; Seong, B.-L. Pharmacophore-based virtual screening: a review of recent applications. Expert Opin. Drug Dis-cov., 2010, 5, 205-222.
143. Barillari, C.; Marcou, G.; Rognan, D. Hot-spots-guided receptor-based pharmacophores (HS-Pharm): A knowledge-based approach to identify ligand-anchoring atoms in protein cavities and prioritize structure-based pharmacophores. J. Chem. Inf. Model., 2008, 48, 1396-1410.
144. Prezeau, L.; Rives, M.-L.; Comps-Agrar, L.; Maurel, D.; Kniazeff, J.; Pin, J.-P. Functional crosstalk between GPCRs: With or without oligomerization. Curr. Opin. Pharmacol., 2010, 10, 6-13.
145. Urban, J.D.; Clarke, W.P.; von Zastrow, M.; Nichols, D.E.; Ko-bilka, B.; Weinstein, H.; Javitch, J.A.; Roth, B.L.; Christopoulos, A.; Sexton, P.M.; Miller, K.J.; Spedding, M; Mailman, R.B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther., 2007, 320, 1-13.
146. Ferré, S.; Franco, R. Oligomerization of G-protein-coupled receptors: A reality. Curr. Opin. Pharmacol., 2010, 10, 1-5.
147. Rovira, X.; Pin, J.-P.; Giraldo, J. The asymmetric/symmetric activation of GPCR dimers as a possible mechanistic rationale for multiple signalling pathways. Trends Pharmacol. Sci., 2010, 31, 15-21.
148. Ferre, S.; Baler, R.; Bouvier, M.; Caron, M. G.; Devi, L. A.; Dur-roux, T.; Fuxe, K.; George, S. R.; Javitch, J. A.; Lohse, M. J.; Mackie, K.; Milligan, G.; Pfleger, K. D. G.; Pin, J.-P.; Volkow, N. D.; Waldhoer, M.; Woods, A. S.; Franco, R. Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol., 2009, 5, 131-134
149. Pin, J.-P.; Comps-Agrar, L.; Maurel, D.; Monnier, C.; Rives, M. L.; Trinquet, E.; Kniazeff, J.; Rondard, P.; Prezeau, L. G-protein-coupled receptor oligomers: two or more for what? Lessons from mGlu and GABAB receptors. J. Physiol., 2009, 587, 5337-5344.
150. Rozenfeld, R.; Devi, L.A. Receptor heteromerization and drug discovery. Trends Pharmacol. Sci., 2010, 31, 124-130.
151. Simpson, L.M.; Taddese, B.; Wall, I.D.; Reynolds, C.A. Bioinfor-matics and molecular modeling approaches to GPCR oligomeriza-tion. Curr. Opin. Pharmacol., 2010, 10, 30-37.
152. Guba, W.; Green, L.G.; Martin, R.E.; Roche, O.; Kratochwil, N.; Mauser, H.; Bissantz, C.; Christ, A.; Stahl, M. From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling. J. Med. Chem., 2007, 50, 6295-6298.
153. Bajorath, J. Computational approaches in chemogenomics and chemical biology: current and future impact on drug discovery. Expert Opin. Drug Discov., 2008, 3, 1371-1376.
154. Stroembergsson, H.; Kleywegt, G. J. A chemogenomics view on protein-ligand spaces. BMC Bioinformatics, 2009, 10, 13.
155. Jacob, L.; Vert, J.-P. Protein-ligand interaction prediction: an improved chemogenomics approach. Bioinformatics, 2008, 24, 2149-2156.
156. Yamanishi, Y; Kotera, M.; Kanehisa, M; Goto, S. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics, 2010, 26, 246-254.
157. Weill, N.; Rognan, D. Development and validation of a novel pro-tein-ligand fingerprint to mine chemogenomic space: Application to G protein-coupled receptors and their ligands. J. Chem. Inf. Model., 2009, 49, 1049-1062.
158. Cases, M.; Mestres, J.A chemogenomic approach to drug discovery: focus on cardiovascular diseases. Drug Discov. Today, 2009, 14, 479-485.
159. Shi, L.; Javitch, J.A. A role for information collection, management, and integration in structure-function studies of G-protein coupled receptors. Curr. Pharm. Des., 2006, 12, 1771-1783 1771
160. Sokal, R.R.; Michener, C.D. A statistical method for evaluating systematic relationships. Univ. Kan. Sci.Bull., 1958, 28, 1409-1438.